Pharma Blog Watch

Bill Leaves Biotechs Behind (Drug Wonks)
In his entry, blogger Robert Goldberg discusses legislation introduced in Congress last week that would create an approval pathway for generic biologics, which he calls "The Clinton-Schumer Biotechnology Elimination Act of 2006."

If the bill passes, "generic firms would have a separate and short track for developing biotech products based on the same mechanism of action without having to go through all the time and expense that a biotech firm has to go through," he writes.